Wolfe Research analyst Andy Chen initiated coverage of Roivant Sciences with an Outperform rating and $17 price target. The firm noted that the company is backed by a robust balance sheet with nearly $7B in cash and minimal debt.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Sciences price target lowered to $13 from $15 at Goldman Sachs
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- Roivant Sciences reports Q3 EPS $6.03, consensus (32c)
- ROIV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jefferies ‘encouraged thus far’ by Arbutus patent hearing
